Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.54 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.48 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.36 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL99739 | 1.00 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrochloric Acid SCHEMBL30643507 | 0.98 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL499352 | 0.98 | — | — | |
| SCHEMBL340834 | 0.98 | — | — | |
| SCHEMBL1158100 | 0.98 | — | — | |
| SCHEMBL31425211 | 0.95 | KDM4E (0.54) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Sulfurous Acid SCHEMBL25414827 | 0.90 | KDM4E (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL25414823 | 0.85 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4632067 | 0.84 | ACE (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Hydrochloric Acid SCHEMBL11112801 | 0.83 | SLC6A5 (0.45) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161255-A1 | NEW THERAPY AND PREVENTION FOR SUPPRESSING AGING-RELATED DISORDERS INCLUDING SARCOPENIA | ASAGI LABS (JP) | 2025-05-22 | — | — | US | claimed |
| CN-119097576-A | Preventing oxidation of flavor raw material and food raw material | 弗门尼舍有限公司 | 2024-12-10 | — | — | CN | claimed |
| EP-4470563-A1 | NEW THERAPY AND PREVENTION FOR SUPPRESSING AGING-RELATED DISORDERS INCLUDING SARCOPENIA | Hayano, Motoshi (JP) | 2024-12-04 | — | — | EP | claimed |
| CN-118973613-A | Novel treatment and prevention of aging-related abnormalities including sarcopenia | 早野元词 | 2024-11-15 | — | — | CN | claimed |
| WO-2023145735-A1 | NEW THERAPY AND PREVENTION FOR SUPPRESSING AGING-RELATED DISORDERS INCLUDING SARCOPENIA | 早野 元詞 | 2023-08-03 | — | — | WO | claimed |
| CN-115996696-A | Prevention, reduction or improvement of odor of elderly people | 弗门尼舍有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-107653575-B | A kind of preparation method for the micro-fluidic chip embedding hyaluronic acid functionalized nano-fiber film | 东华大学 | 2019-07-23 | — | — | CN | claimed |
| CN-107653575-A | A kind of preparation method for the micro-fluidic chip for embedding hyaluronic acid functionalized nano-fiber film | 东华大学 | 2018-02-02 | — | — | CN | claimed |
| CN-105086001-A | Hyaluronic acid-gelatin/acrylamide double-network aquagel and preparation method thereof | UNIV CHANGCHUN TECHNOLOGY | 2015-11-25 | — | — | CN | claimed |
| US-20140377328-A1 | INTRAORAL SOLUBLE-TYPE FILM PREPARATION | KYUKYU PHARMACEUTICAL CO., LTD. (JP) | 2014-12-25 | — | — | US | claimed |
| WO-2008027350-A2 | ACETAMINOPHEN PHARMACEUTICAL COMPOSITIONS | AAIPHARMA INC. (US) | 2008-03-06 | — | — | WO | claimed |
| CN-1822861-A | Stable radiopharmaceutical compositions and methods of preparation | BRACCO IMAGING SPA (IT) | 2006-08-23 | — | — | CN | claimed |
| EP-4393512-B1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEM CORP (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-3603648-B1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | SHIONOGI & CO (JP) | 2025-09-17 | — | — | EP | disclosed |
| CN-114729004-B | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025105451-A1 | SOLID PREPARATION | 第一三共ヘルスケア株式会社 | 2025-05-22 | — | — | WO | disclosed |
| EP-0627218-A1 | FAST SOLUBLE TABLET | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-12-07 | — | — | EP | disclosed |
| US-5368861-A | Gastric preparation with sustained release | NIPPON SHINYAKU CO., LTD. (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0617960-A1 | Use of pyridoxal derivatives for the manufacture of a medicament for the treatment of cataract | Senju Pharmaceutical Co., Ltd. (JP) | 1994-10-05 | — | — | EP | disclosed |
| EP-0497977-A1 | GASTRIC PREPARATION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161255-A1 | NEW THERAPY AND PREVENTION FOR SUPPRESSING AGING-RELATED DISORDERS INCLUDING SARCOPENIA | MTPN, TNNC1, MSTN | PTGS2 3901/4885ACE 174/4885PTGS1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.